8,700 Studies Reviewed. 87.0% Found Biological Effects. The Evidence is Clear.
Shield Your Body
Cancer & Tumors434 citations

Choi Y-K, Urnukhsaikhan E, Yoon H-H, Seo Y-K, Park J-K

Bioeffects Seen

Authors not listed · 2016

Share:

This blood cancer genetics study was misclassified as EMF research but shows scientific rigor needed for EMF health studies.

Plain English Summary

Summary written for general audiences

Researchers used advanced genetic sequencing to identify specific gene mutations in patients with rare blood disorders called histiocytic neoplasms. They discovered new genetic targets for treatment and successfully treated some patients with targeted drugs. This study advances precision medicine for these challenging blood cancers.

Why This Matters

This genetic research on histiocytic neoplasms represents important progress in cancer medicine, but it's not directly related to EMF health effects. The study appears to have been incorrectly categorized in our EMF research database. However, it does highlight how modern molecular techniques can uncover disease mechanisms - the same rigorous scientific approach we need when studying EMF health effects. While this particular research focuses on genetic mutations driving blood cancers, the methodology demonstrates the type of comprehensive analysis that could advance our understanding of how electromagnetic field exposure might influence cellular pathways and gene expression in exposed tissues.

Exposure Information

Specific exposure levels were not quantified in this study.

Cite This Study
Unknown (2016). Choi Y-K, Urnukhsaikhan E, Yoon H-H, Seo Y-K, Park J-K.
Show BibTeX
@article{choi_y_k_urnukhsaikhan_e_yoon_h_h_seo_y_k_park_j_k_ce4321,
  author = {Unknown},
  title = {Choi Y-K, Urnukhsaikhan E, Yoon H-H, Seo Y-K, Park J-K},
  year = {2016},
  doi = {10.1158/2159-8290.CD-15-0913},
  
}
DOI: 10.1158/2159-8290.CD-15-0913PubMed: 26566875

Quick Questions About This Study

Histiocytic neoplasms are rare blood disorders where abnormal immune cells (dendritic cells or macrophages) accumulate in tissues. They include Langerhans cell histiocytosis and non-Langerhans cell histiocytosis, both challenging to treat.
BRAFV600E mutations occur in about 50% of patients and provided the first targeted treatment option. However, patients without this mutation needed different therapeutic approaches, which this study helped identify.
Researchers found kinase fusions involving BRAF, ALK, and NTRK1 genes, plus activating mutations in MAP2K1 and ARAF. These discoveries opened new treatment pathways for previously difficult-to-treat patients.
Yes, patients with MAP2K1 mutations responded to MEK inhibitors, while those with ARAF mutations responded to RAF inhibitors like sorafenib. This demonstrated the value of precision medicine approaches.
Different patients have different genetic drivers of their disease. Comprehensive analysis identifies which specific mutations are present, allowing doctors to select the most effective targeted therapy for each individual patient.